2 withdrawn, 1 active not recruiting, 1 completed, 1 recruiting. 2 Not applicable, 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 1, Recruiting 1 |
| Phase 1 | 1 | Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Multiple Sclerosis (Relapsing Remitting): new trials by email Literature Review of Multiple Sclerosis (Relapsing Remitting) trials Research Report on Multiple Sclerosis (Relapsing Remitting)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis CABA-201 - Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS) | Phase 1 / Phase 2 | Withdrawn | Cabaletta Bio | 2026-06-01 | 2026-06-25 | |
| Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis Perturbation Training, Treadmill Walking - Multiple Sclerosis (Relapsing Remitting) | Not applicable | Recruiting | Georgia State University | 64 | 2026-04-06 | 2026-06-17 |
| Comparison of Efficacy and Safety in Patients Switching From MabThera® to Rixathon® in Relapsing-Remitting Multiple Sclerosis MS (Multiple Sclerosis), Multiple Sclerosis (MS) - Relapsing-remitting | Active not recruiting | Uppsala University | 184 | 2025-01-01 | 2025-11-19 | |
| Safety and Efficacy of Fingolimod in MS Patients in China fingolimod, Placebo (6mos) + open label fingolimod (6 mos) - Multiple Sclerosis (Relapsing Remitting) | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2014-06-01 | 2017-04-21 | |
| Multiple Sclerosis and Progressive Resistance Training Training - Multiple Sclerosis (Relapsing Remitting) | Not applicable | Completed | University of Aarhus | 35 | 2012-02-01 | 2014-12-02 |
Multiple Sclerosis, Relapsing-Remitting (5) · Multiple Sclerosis (3) · Multiple Sclerosis, Chronic Progressive (2) · Autoimmune Diseases (1) · Charcot-Marie-Tooth disease, Type 1F (1) · Disease Progression (1)
Autoimmune Diseases of the Nervous System (5) · Demyelinating Autoimmune Diseases, CNS (5) · Demyelinating Diseases (5) · Immune System Diseases (5) · Nervous System Diseases (5) · Autoimmune Diseases (4) · Chronic Disease (2) · Disease Attributes (2) · Multiple Sclerosis (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2)
Cabaletta Bio (1) · Georgia State University (1) · Novartis Pharmaceuticals (1) · University of Aarhus (1) · Uppsala University (1)
Denmark (1) · Sweden (1) · United States (1)
Joachim Burman, MD, PhD (1) · Kristian Vissing, Ph.D. (1) · Thor Petersen, Dr.med (1) · Ulrik Dalgas, Ph.D. (1)